Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Saved in:
| Title: | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. |
|---|---|
| Authors: | Qin S; Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, China., Chen M; Sun Yat-sen University Cancer Center, Guangzhou, China., Cheng AL; National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan., Kaseb AO; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kudo M; Kindai University, Osaka, Japan., Lee HC; Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Yopp AC; Department of Surgery, Division of Surgical Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA., Zhou J; Zhongshan Hospital, Fudan University, Shanghai, China., Wang L; Fudan University Shanghai Cancer Center, Shanghai, China., Wen X; 1st Hospital of Jilin University, Jilin, China., Heo J; College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea., Tak WY; Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea., Nakamura S; Himeji Red Cross Hospital, Hyogo, Japan., Numata K; Yokohama City University Medical Center, Yokohama, Japan., Uguen T; Hôpital de Pontchaillou, Rennes, France., Hsiehchen D; Department of Internal Medicine, Division of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA., Cha E; Genentech, South San Francisco, CA, USA., Hack SP; Genentech, South San Francisco, CA, USA., Lian Q; Genentech, South San Francisco, CA, USA., Ma N; Genentech, South San Francisco, CA, USA., Spahn JH; Genentech, South San Francisco, CA, USA., Wang Y; Fudan University Shanghai Cancer Center, Shanghai, China; Genentech, South San Francisco, CA, USA., Wu C; Roche (China) Holding, Shanghai, China., Chow PKH; National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, Singapore. Electronic address: pierce.chow@duke-nus.edu.sg. |
| Corporate Authors: | IMbrave050 investigators |
| Source: | Lancet (London, England) [Lancet] 2023 Nov 18; Vol. 402 (10415), pp. 1835-1847. Date of Electronic Publication: 2023 Oct 20. |
| Publication Type: | Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
